Advances in the management of metastatic gastric cancer: current strategies and emerging therapeutics - PubMed
14 hours ago
- #biomarker-informed treatment
- #metastatic gastric cancer
- #emerging therapeutics
- Metastatic gastric cancer remains a major global health challenge with poor long-term outcomes.
- Treatment has evolved with biomarker-informed strategies, including immune checkpoint inhibitors and targeted therapies for specific subgroups.
- Standard first-line treatment relies on fluoropyrimidine-platinum chemotherapy, with biomarker-driven agents added for improved efficacy.
- Most patients experience disease progression, and durable responses are rare.
- Ongoing research focuses on new targets like FGFR2b and novel strategies involving HER2 and claudin 18.2.
- Emerging treatment modalities include antibody-drug conjugates, bispecific antibodies, and cellular therapies.
- Complementary platforms like circulating tumour DNA and theranostic agents are being explored for better treatment guidance and monitoring.